The Current Ratio as of November 2024 (TTM) for Avalo Therapeutics, Inc. (AVTX) is 1.42

According to Avalo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.42. This represents a change of 19.61% compared to the average of 1.19 of the last 4 quarters.

Avalo Therapeutics, Inc. (AVTX) Historical Current Ratio (quarterly & annually)

How has AVTX Current Ratio performed in the past?

The mean historical Current Ratio of Avalo Therapeutics, Inc. over the last ten years is 1.81. The current 1.42 Current Ratio has changed 7.75% with respect to the historical average. Over the past ten years (40 quarters), AVTX's Current Ratio was at its highest in in the September 2017 quarter at 5.82. The Current Ratio was at its lowest in in the June 2023 quarter at 0.33.

Avalo Therapeutics, Inc. (AVTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Avalo Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Avalo Therapeutics, Inc. (AVTX) Average Current Ratio

How has AVTX Current Ratio performed in the past?

The current Current Ratio of Avalo Therapeutics, Inc. (AVTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Avalo Therapeutics, Inc. (AVTX) Current Ratio vs. Peers

How is AVTX’s Current Ratio compared to its peers?

Avalo Therapeutics, Inc.’s Current Ratio is less than AnaptysBio, Inc. (10.23), less than Arcellx, Inc. (4.29), less than Structure Therapeutics Inc. (27.63), less than Aerovate Therapeutics, Inc. (8.78), less than ALX Oncology Holdings Inc. (4.82), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Acrivon Therapeutics, Inc. Common Stock (12.75), less than PMV Pharmaceuticals, Inc. (13.98), less than Molecular Partners AG (14.33), less than Mineralys Therapeutics, Inc. (8.55), greater than Alzamend Neuro, Inc. (0.49), less than Virax Biolabs Group Limited (25.94), greater than Kiromic BioPharma, Inc. (0.22), less than Benitec Biopharma Inc. (15.01), less than Century Therapeutics, Inc. (10.39), less than Edgewise Therapeutics, Inc. (26.35), less than C4 Therapeutics, Inc. (6.31), less than Cullinan Oncology, Inc. (24.46), less than Miromatrix Medical Inc. (3.46), greater than ZIVO Bioscience, Inc. (0.17), less than Bionomics Limited (3.30),

Build a custom stock screener for Avalo Therapeutics, Inc. (AVTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avalo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Avalo Therapeutics, Inc. (AVTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Avalo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.